328918-89-4

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 328918-82-7 2-(4-bromophenyl)-5-methyl-4-oxazoleacetic acid 
• 328918-83-8 [2-(4-bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 
• 328918-81-6 2-(4-bromophenyl)-4-(chloromethyl)-5-methyl-1,3-oxazole 
• 328918-80-5 4,5-dimethyl-2-(4-bromophenyl)-oxazole oxide 
• 4124-41-8 p-toluenesulfonylanhydride 
• 328918-84-9 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol 

Downstream Products

• 328918-98-5 toluene-4-sulfonic acid 2-[2-(3-bromophenyl)-5-methyloxazol-4-yl]ethyl Ester 
• 328918-90-7 2-(4-{2-[2-(4-bromophenyl)-5-methyloxazol-4-yl]ethoxy}phenoxy)-2-methylpropionic acid ethyl ester 
• 328918-91-8 2-(4-bromophenyl)-5-methyl-4-vinyloxazole 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Modulators of peroxisome proliferator activated receptors

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented b

Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: A new class of dual PPARα/γ agonists

Propionic acid derivative 8, which was designed and synthesized based on putative pharmacophores of known PPARγ- and PPARα-selective compounds, exhibits potent dual PPARα/γ agonist activity as demonstrated by in vitro binding and dose overlap in the newly